Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

gonyzyf.wordpress.com
For latest information on the Companuy andits products, please follow Accesz on and . Access has announced that MuGard(TM) was launched in Germany, Italy, UK, Greece and the Nordicf countries by its Europeancommercial . Under a licens e from Access Pharmaceuticals Inc, SpePharm is responsible for manufacturing, regulatort approval and commercialization in the 27 countriexsof Europe. SpePharm plans to launch MuGarsd in the rest of Europe over the comingg 12 to18 months. The license agreement includes royalties on net salesto Access.
"SpePharm and Accesd are pleased with the commercial launch of MuGardcin Europe, and while it is stillp in the early days, initial feedback has been positive," said , Vice Presidentf of Business Development at "SpePharm is working hard to securd reimbursement from the individual governmental which we believe will greatlyy enhance initial product adoption and ongoing marketing effortws to reach and penetrates the target population of patients requirinvg this important treatment option.," he continued.
MuGard is a ready-to-use mucoadhesive oral woundd rinse for the management of oral a debilitating side effect of many anticancer Upto 40% of all patients receiving chemotheraphy and/or radiotherapy develop moderate to severr mucositis, and almost all patientsz receiving radiotherapy for head and neck cancer and thosew undergoing stem cell transplantation develop Updated clinical practice guidelines for the prevention and treatmentr of mucositis recommend the use of a preventivde oral care regimen as part of routine supportive care alonhg with a therapeutic oral care regimejn if mucositis develops.
The markeg for the treatment of oral mucositis is estimatesd to be in excessof $1 billion MuGard forms a protective coating over the oral mucosz when swirled gently around the In a comparison of cancer patients receiving standardx mucositis care with those patients receivinb MuGard, the incidence and severity of mucositis was significantlhy lower in the MuGard treated group using a validated scale for the assessmentf of oral mucositis. Access Pharmaceuticals, Inc. is an emerging biopharmaceuticall company that develops and commercializews propriety products for the treatmen t and supportive care ofcancer patients.
Access' products include ProLindac(TM), currently in Phase 2 clinica l testing of patients withovarian cancer, and MuGard(TM) for the managemengt of patients with mucositis. The company also has other advanced drug delivert technologiesincluding Cobalamin(TM)-mediated targeted deliverg and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesisw factor and is targeted to breasyt cancer; and Thiarabine, a new generatiojn nucleoside analog which has demonstrated both pre-clinical and clinical activity in certainn cancers.
For additional information on Access Pharmaceuticals, please visirt our website at . This press releaser contains certain statements thatare forward-looking within the meaningb of Section 27a of the Securities Act of 1933, as and that involve risks and These statements include those relating to: clinicap trial plans and timelines and clinical resultsw for ProLindac and product candidates acquired in the MacroChem our ability to execute licensing agreements in the future, Access' planes to continue and initiate clinical trials, the value of its producta in the market (includingb MuGard and the size of the overall market for mucositis its ability to achieve clinical and commercial succesd and its ability to successfully develop marketes products.
These statements are subjectg tonumerous risks, including but not limitee Access' need to obtain additional financinb in order to continue the clinical trial and operationws and to the risks detaileed in Access' Annual Reports on Form 10-K and other reports filec by Access with the Securities and Exchang Commission. SOURCE Access Pharmaceuticals, Inc.